SI-BONE's (SIBN) "Overweight" Rating Reiterated at Cantor Fitzgerald

SI-BONE (NASDAQ:SIBN - Get Free Report)'s stock had its "overweight" rating reaffirmed by stock analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald's price objective would indicate a potential upside of 75.44% from the company's previous close.

A number of other brokerages have also recently weighed in on SIBN. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of SI-BONE in a research report on Tuesday. Truist Financial restated a "buy" rating and set a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $24.40.

SI-BONE Price Performance

SIBN opened at $14.25 on Tuesday. The company's 50 day simple moving average is $14.53 and its 200 day simple moving average is $14.69. SI-BONE has a 1 year low of $11.70 and a 1 year high of $19.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market capitalization of $606.04 million, a PE ratio of -15.49 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. As a group, sell-side analysts expect that SI-BONE will post -0.78 EPS for the current year.

Insiders Place Their Bets

In other SI-BONE news, insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,775 shares of company stock worth $95,711 over the last three months. Insiders own 3.90% of the company's stock.

Institutional Trading of SI-BONE

Hedge funds have recently made changes to their positions in the stock. Virtus Fund Advisers LLC bought a new stake in SI-BONE in the 4th quarter worth $40,000. Mainstream Capital Management LLC bought a new stake in shares of SI-BONE during the 4th quarter valued at about $53,000. GAMMA Investing LLC lifted its position in SI-BONE by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares in the last quarter. R Squared Ltd bought a new stake in shares of SI-BONE during the 4th quarter valued at $73,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of SI-BONE during the fourth quarter valued at approximately $97,000. 98.11% of the stock is owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.